Optima Health (STU:J3N) Research & Development: €0.0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:J3N Optima Health PLC STU:J3N
24 GF Score
Price €2.18
! 2 Warning Signs
View Full Analysis

What is Optima Health Research & Development?

Optima Health STU:J3N 24 Research & Development is €0.0 Mil as of Sep. 2025. GuruFocus rates STU:J3N with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Optima Health's Research & Development for the six months ended in Sep. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was €0.0 Mil.

Optima Health  (STU:J3N) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Optima Health Research & Development Related Terms

Optima Health Research & Development Historical Data

* Premium members only.

The historical data trend for Optima Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Optima Health Research & Development Chart

Optima Health Annual Data
Trend Mar22 Mar23 Mar24 Mar25
Research & Development
0.00 0.00 0.00 0.00

Optima Health Semi-Annual Data
Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
STU:J3N
24GF Score
Optima Health PLC STU:J3N
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Optima Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Optima Health (STU:J3N) has a Research & Development of €0.0 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Optima Health and its competitors.
Is Optima Health's Research & Development too high?
Optima Health's current Research & Development is €0.0 Mil. Overall, Optima Health has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Optima Health's Research & Development compare to VEEV and BTSG?
Optima Health's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Optima Health and its competitors. Optima Health's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optima Health stock overvalued right now?
Optima Health (STU:J3N) has a current Research & Development of €0.0 Mil. The current Research & Development is €0.0 Mil. Optima Health's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Optima Health (STU:J3N), the current Research & Development is €0.0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Optima Health Business Description

Other Exchanges OPT:UKJ3N:Germany
Address 2 Hayland Street, Meadow Court, Sheffield, GBR, S9 1BY
Optima Health PLC is a provider of technology-enabled corporate health and wellbeing solutions in the occupational health sector. The group offers a comprehensive range of flexible and progressive services, from statutory-driven workplace health surveillance medicals to proactive and preventive interventions, as well as workplace health advice and attendance management assessments. These services are ultimately rehabilitation programs and pathways designed to help people return to work.
24GF Score

Get the complete analysis for STU:J3N

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18
Price